Abstract
Topic: Herpes simplex virus (HSV) and varicella zoster virus (VZV) are the most common ocular pathogens associated with infectious anterior uveitis. Currently, there are a number of antiviral agents administered to treat viral anterior uveitis (VAU). However, there is no consensus or guidelines about the most appropriate approach leading for the best treatment outcomes with fewer ocular complications.Clinical Relevance: To perform a systematic review and meta-analysis of the efficacy of different antiviral therapies in the management of anterior uveitis secondary to HSV and VZV.Methods: We searched PubMed, Web of Science, CINAHL, OVID, and Embase up to January 2020. Randomized trials, non-randomized intervention studies, controlled before and after studies and observational studies assessing the effect of oral and or topical treatments for VAU were considered. Data extraction and analysis with evaluation of the risk of bias in the included trials were performed.Results: Oral acyclovir demonstrated a statistically significant good treatment outcome in the management of VZV anterior uveitis (vs. placebo) (OR 0.26, 95% CI 0.11–0.59), but did not have similar effect in HSV anterior uveitis (OR 0.47, 95% CI 0.15–1.50). In the treatment of VZV anterior uveitis, there was significant superiority of oral acyclovir−7 day course—over topical acyclovir (OR 4.17, 95% CI 1.28–13.52). Whereas, there was no significant superiority of one of the following treatment regimens over the others: topical acyclovir over topical corticosteroids (OR 1.86, 95% CI 0.67–5.17), and oral acyclovir−7 day course—over oral acyclovir−14 day course—(OR 0.21, 95% CI 0.01–4.50) or oral valaciclovir (OR 1.40, 95% CI 0.48–4.07).Conclusion: Treatment of HSV and VZV anterior uveitis is currently based on individual experiences and limited literature, largely due to weak clinical trial evidence in this regard. Our results highlight the existence of a substantial gap in our evidence base. This finding might contribute to future research studies to ascertain the role of different antiviral therapies in the treatment of VAU.Systematic Review Registration: PROSPERO registration number: CRD420202 00404.
Highlights
Viral anterior uveitis (VAU) is the most common form of infectious uveitis, accounting for more than 10% of all cases of anterior uveitis (1)
Considering the overlap between clinical features suggestive of herpes simplex virus (HSV) and varicella zoster virus (VZV) anterior uveitis, once a viral etiology is suspected, polymerase chain reaction (PCR)-based analysis of aqueous humor sample may be used by the clinicians for confirming the diagnosis (5–8)
The study protocol investigating the role of antiviral therapy for VZV and HSV induced anterior uveitis can be found at PROSPERO, international database of prospectively registered systematic reviews
Summary
Viral anterior uveitis (VAU) is the most common form of infectious uveitis, accounting for more than 10% of all cases of anterior uveitis (1). Different members of the herpes virus family, including herpes simplex virus (HSV) and varicella zoster virus (VZV), are considered for the differential diagnosis when a viral etiology is suspected. The presence of herpetic dermatitis, including vesicles occurring at the border of the eyelids and the zoster vesicular rash, or dendritic keratitis can provide a strong corroborative evidence for the diagnosis, but these findings are often absent. The presumptive diagnosis is based on ocular features, including unilateral involvement, reduced corneal sensation, keratic precipitates, iris atrophy and rise in intraocular pressure, with a course of the disease that is commonly recurrent (2–4). Considering the overlap between clinical features suggestive of HSV and VZV anterior uveitis, once a viral etiology is suspected, polymerase chain reaction (PCR)-based analysis of aqueous humor sample may be used by the clinicians for confirming the diagnosis (5–8). The detection of the pathogen allows a more targeted therapy with the aim of limiting further spread of the virus and avoiding secondary tissue damage
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have